GuidelineMMWR. Morbidity and mortality weekly report2023
Use of the Pfizer Respiratory Syncytial Virus Vaccine During Pregnancy for the Prevention of Respiratory Syncytial Virus-Associated Lower Respiratory Tract Disease in Infants: Recommendations of the Advisory Committee on Immunization Practices - United States, 2023.
Guideline in MMWR. Morbidity and mortality weekly report, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 173 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
173 citing papers in PubMed, 5 syntheses or guidelines pooled it, 250 citations in OpenAlex.
- Maternal RSV vaccination for infant protection: A systematic review and meta-analysis of phase 3 trials with an integrated economic evaluation.International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · 2026Pooled it
- Efficacy and safety of maternal RSV vaccination against infant lower respiratory tract infections: a systematic review and meta-analysis.Frontiers in public health · 2026Pooled it
- Use of Clesrovimab for Prevention of Severe Respiratory Syncytial Virus-Associated Lower Respiratory Tract Infections in Infants: Recommendations of the Advisory Committee on Immunization Practices - United States, 2025.MMWR. Morbidity and mortality weekly report · 2025Guideline
- Respiratory Syncytial Virus among People Living with HIV: Is There a Case for Rolling Out Prophylaxis? A Viewpoint Based on a Systematic Review.Pathogens (Basel, Switzerland) · 2024Pooled it
- Advisory Committee on Immunization Practices Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger - United States, 2024.MMWR. Morbidity and mortality weekly report · 2024Guideline
- Maternal RSV Vaccination, Infant Nirsevimab, or Both: Interim Analysis of a Randomized Trial.Pediatrics · 2026Trial
- The effect of preexisting antibodies from Tdap vaccination during pregnancy on infant antibody responses to the pertussis-containing vaccines.Human vaccines & immunotherapeutics · 2025Trial
- Expenditures attributable to infant lower respiratory tract infection due to respiratory syncytial virus in the US: A real-world study using the PharMetrics Plus Database, 2015-2023.Human vaccines & immunotherapeutics · 2026Article
- Review
- Influenza A and other respiratory viruses show distinct associations with acute respiratory presentations and temporal correlation with hospital admissions.Journal of medical microbiology · 2026Article
- Article
- A comprehensive look at Respiratory Syncytial Virus (RSV): from pathogenesis to prevention.Tropical diseases, travel medicine and vaccines · 2026Review
- Comparison of Respiratory Syncytial Virus (RSV)-Specific Antibody Durability in Pregnant/Postpartum Individuals and Older Adults After RSV Vaccination.The Journal of infectious diseases · 2026Article
- CAUSAL-RSV: A study protocol for a causal mediation analysis of RSV vaccine effects in infants using real-world data.medRxiv : the preprint server for health sciences · 2026Article
- Maternal Immunization Against Respiratory Syncytial Virus: An Integrative Review of Efficacy, Safety, and Implementation.Vaccines · 2026Review
- Review
- Correlations and Timeliness of Respiratory Syncytial Virus Surveillance Indicators-United States, 2018-2024.Influenza and other respiratory viruses · 2026Article
- Evaluating Analytic Approaches to Determining Respiratory Syncytial Virus Seasonality-United States, 2014-2024.Influenza and other respiratory viruses · 2026Article
- Respiratory Syncytial Virus Immunization Intention During Pregnancy and Infancy.JAMA network open · 2026Article
- Article
113 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Respiratory syncytial virus (RSV) is the leading cause of hospitalization among U.S. infants. Nirsevimab (Bevfortus, Sanofi and AstraZeneca) is recommended to prevent RSV-associated lower respiratory tract infection (LRTI) in infants. In August 2023, the Food and Drug Administration (FDA) approved RSVpreF vaccine (Abrysvo, Pfizer Inc.) for pregnant persons as a single dose during 32-36 completed gestational weeks (i.e., 32 weeks and zero days' through 36 weeks and 6 days' gestation) to prevent RSV-associated lower respiratory tract disease in infants aged <6 months. Since October 2021, CDC's Advisory Committee on Immunization Practices (ACIP) RSV Vaccines Pediatric/Maternal Work Group has reviewed RSV epidemiology and evidence regarding safety, efficacy, and potential economic impact of pediatric and maternal RSV prevention products, including RSVpreF vaccine. On September 22, 2023, ACIP and CDC recommended RSVpreF vaccine using seasonal administration (i.e., during September through end of January in most of the continental United States) for pregnant persons as a one-time dose at 32-36 weeks' gestation for prevention of RSV-associated LRTI in infants aged <6 months. Either maternal RSVpreF vaccination during pregnancy or nirsevimab administration to the infant is recommended to prevent RSV-associated LRTI among infants, but both are not needed for most infants. All infants should be protected against RSV-associated LRTI through use of one of these products.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.